Login

Financial Snapshot

Revenue
TTM
$1.080B
Gross Margin
TTM
64.89%
Net Income
TTM
-$433.2M
Current Assets
2026 Q1
Current Liabilities
2026 Q1
Current Ratio
2026 Q1
468.09%
Total Assets
2026 Q1
Total Liabilities
2026 Q1
Book Value
2026 Q1
-$181.1M
Cash
2026 Q1
P/E
Last 4 Quarters
N/A
Free Cash Flow
TTM
-$237.1M

Stock Price

Loading...
Market Cap: $17.261 Billion

About Guardant Health Inc

Guardant Health (NASDAQ: GH) is a precision oncology company that develops and commercializes blood-based genomic tests used to detect and monitor cancer. Revenue comes primarily from clinical test sales to oncologists and cancer centers, with additional revenue from biopharmaceutical partnerships where drug developers use Guardant's sequencing technology in clinical trials. The company's core products include the Guardant360 liquid biopsy test for advanced cancer profiling and the Shield test for colorectal cancer screening in average-risk adults. Guardant competes in the liquid biopsy and cancer screening markets against both established diagnostics companies and molecular testing specialists. The company is headquartered in Redwood City, California and files annually with the SEC as a well-known seasoned issuer. The filing excerpts available do not support disclosure of specific FY2025 revenue figures, segment breakdowns, customer concentration data, or leadership tenure details, so those are omitted.

Revenue model
Transactional revenue from clinical liquid biopsy test sales to oncologists and health systems, plus biopharmaceutical partnership revenue from drug developers using Guardant's sequencing platform in clinical development programs.
Products and services
Guardant360 (advanced cancer genomic profiling), Shield (colorectal cancer screening for average-risk adults), liquid biopsy tests, biopharmaceutical development services.
Customers and end markets
Oncologists, cancer treatment centers, health systems, biopharmaceutical companies conducting oncology drug trials, average-risk adults eligible for colorectal cancer screening.
Value-chain role
Diagnostic test developer and laboratory service provider sitting between cancer patients and treating oncologists, and between biopharmaceutical sponsors and clinical trial genomic data.

Source: SEC 10-K, filed 2026-02-19

Industry: Services-Medical Laboratories Peers: AMN Healthcare Services Inc Option Care Health Inc Chemed Corp CVS Health Corp LHC Group, Inc MSP Recovery Inc Oak Street Health, Inc. Privia Health Group Inc Premier, Inc. Signify Health, Inc.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support